AbCellera Biologics Stock (NASDAQ:ABCL), Analyst Ratings, Price Targets, Predictions

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Keybanc on May 8, 2024. The analyst firm set a price target for $7.00 expecting ABCL to rise to within 12 months (a possible 83.23% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Keybanc, and AbCellera Biologics maintained their overweight rating.

The last upgrade for AbCellera Biologics Inc happened on February 22, 2024 when Benchmark raised their price target to N/A. Benchmark previously had a hold for AbCellera Biologics Inc.

There is no last downgrade for AbCellera Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $8.00 to $7.00. The current price AbCellera Biologics (ABCL) is trading at is $3.82, which is out of the analyst’s predicted range.